| Synapsin-1 | |
|---|---|
| Protein Name | Synapsin-1 |
| Gene Symbol | [SYN1](/genes/SYN1) |
| UniProt ID | [P17600](https://www.uniprot.org/uniprot/P17600) |
| Alternative Names | Synapsin I, SYN1 |
| Protein Family | Synapsin family |
| Molecular Weight | 74 kDa (705 amino acids) |
| Subcellular Localization | Presynaptic terminal (synaptic vesicles) |
| Brain Expression | Exclusively neuronal, highest in hippocampus and cerebral cortex |
Synapsin-1 is a neuronal phosphoprotein encoded by the SYN1 gene that regulates synaptic vesicle clustering, mobilization, and neurotransmitter release at presynaptic terminals[1]. It is the most extensively studied member of the synapsin family (synapsin-1 through -3 in mammals) and serves as a canonical marker of synaptic integrity. Synapsin-1 is widely used as a synaptic biomarker in cerebrospinal fluid (CSF) for neurodegenerative diseases, where elevated or reduced levels reflect synaptic pathology[2].
Synapsin-1 is a 705-amino acid phosphoprotein with a modular domain architecture:
| Domain | Amino Acids | Function |
|---|---|---|
| Domain A (N-terminal) | 1-120 | Membrane-binding, synaptic vesicle association via lipid interactions |
| Domain B (linker) | 120-280 | Flexible region; contains Ser9 (PKA site) |
| Domain C | 280-420 | ATP-binding site (binds ATP with high affinity); critical for vesicle clustering |
| Domain D (linker) | 420-520 | Flexible linker region |
| Domain E (C-terminal) | 520-705 | Protein-protein interactions, targets synapsin to synaptic vesicles |
Domain C contains a conserved ATP-binding cassette (ABC) fold. ATP binding induces a conformational change that increases synapsin's affinity for synaptic vesicles, promoting clustering. ATP hydrolysis releases synapsin from vesicles, allowing vesicle mobilization for release. This ATP-dependent cycling is the basis for synapsin's activity-dependent regulation of vesicle availability[3].
Synapsin-1 is phosphorylated at multiple sites that regulate its function:
| Kinase | Site(s) | Effect on Function |
|---|---|---|
| Protein Kinase A (PKA) | Ser9 | Reduces membrane binding, promotes vesicle release |
| CaMKII | Ser603 (major), Ser566 | Dissociates synapsin from vesicles, mobilizes release-ready vesicles |
| MAPK/ERK | Multiple sites | Activity-dependent regulation |
| CDK5 | Ser549 | Modulates synaptic vesicle dynamics |
| PKC | Ser139, Ser9 | Context-dependent regulation |
During development and in mature neurons, synapsin-1 is the primary organizer of the synaptic vesicle pool at presynaptic terminals:
This system ensures that not all vesicles are released simultaneously — synapsin maintains a releasable reserve that can be mobilized during sustained or high-frequency activity[4].
Synapsin-1 modulates multiple aspects of neurotransmitter release:
During neuronal development:
Synapsin-1 is released into CSF when synapses are damaged, making it a direct measure of synaptic loss. CSF synapsin-1 levels correlate with:
Synapsin-1 dysfunction is among the earliest features of AD:
Synaptic loss as the strongest correlate:
Relationship with amyloid-beta:
CSF biomarker:
Dopaminergic synapse dysfunction:
Synaptic vulnerability:
SYN1 mutations are associated with epilepsy in humans and animal models[5]:
Synapsin-1 alterations have been reported in ALS:
AAV-mediated synapsin-1 delivery is under investigation for neurodegenerative diseases[6]:
CSF synapsin-1 is established as a synaptic biomarker[2:2]:
| Approach | Mechanism | Development Status |
|---|---|---|
| Kinase modulators | Enhance synapsin-1 phosphorylation | Research |
| Synaptic vesicle stabilizers | Preserve vesicle pools | Preclinical |
| Synapsin-1 replacement | AAV gene therapy | Preclinical |
Greengard P, et al. The synapsins. Annual Review of Cell Biology. 1993. ↩︎
Bhattacharya S, et al. CSF synapsin-1 as a biomarker of synaptic loss in Alzheimer's disease. Alzheimer's & Dementia. 2022. ↩︎ ↩︎ ↩︎
Cesca F, et al. Synapsin function in neuronal development. Nature Reviews Neuroscience. 2010. ↩︎
Fornasiero EF, et al. Synapsins: from activity-dependent buffering to neuronal development. Frontiers in Cellular Neuroscience. 2010. ↩︎
Porton B, et al. Synapsin mutations and epilepsy. Brain. 2021. ↩︎
Bhutani S, et al. AAV-mediated synapsin-1 gene therapy for neurodegenerative diseases. Molecular Therapy. 2022. ↩︎